הלוואות ואשראי לטווח ארוך של החברה calliditas.se (CALT)

Calliditas Therapeutics (CALT) delegates clinical trials and drug manufacturing to third-party contractors, creating a dependency on external capacities. Price action on GURU.Markets, where the indicator stands at 0.09, confirms business resilience driven by the ownership of exclusive patents in a narrow niche. Simultaneously, Calliditas Therapeutics (CALT) is implementing strict environmental standards in its laboratories and transitioning to biodegradable packaging to minimize plastic waste.

This indicator measures total liabilities with a maturity of more than one year to assess financial stability. The calculation is based on an analysis of the liability structure, identifying the business's dependence on borrowed funds amid volatile rates. The current level of the business's long-term debt capital demonstrates the degree of leverage. For Calliditas Therapeutics (CALT), a low debt load complements the strong cash flow from Tarpeyo sales. This minimizes risks while awaiting a strategic acquisition.